These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 8585718)

  • 1. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa.
    Weiss K; Lapointe JR
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2411-4. PubMed ID: 8585718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Balke B; Hogardt M; Schmoldt S; Hoy L; Weissbrodt H; Häussler S
    Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):25-30. PubMed ID: 16402226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa.
    Lang BJ; Aaron SD; Ferris W; Hebert PC; MacDonald NE
    Am J Respir Crit Care Med; 2000 Dec; 162(6):2241-5. PubMed ID: 11112146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.
    Pedersen SS; Pressler T; Jensen T; Rosdahl VT; Bentzon MW; Høiby N; Koch C
    J Antimicrob Chemother; 1987 Jan; 19(1):101-7. PubMed ID: 3104273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation.
    Saiman L; Mehar F; Niu WW; Neu HC; Shaw KJ; Miller G; Prince A
    Clin Infect Dis; 1996 Sep; 23(3):532-7. PubMed ID: 8879776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.
    Manno G; Cruciani M; Romano L; Scapolan S; Mentasti M; Lorini R; Minicucci L
    Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
    Smith AL; Fiel SB; Mayer-Hamblett N; Ramsey B; Burns JL
    Chest; 2003 May; 123(5):1495-502. PubMed ID: 12740266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.
    Dundar D; Otkun M
    Yonsei Med J; 2010 Jan; 51(1):111-6. PubMed ID: 20046523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
    Scribner RK; Marks MI; Weber AH; Tarpay MM; Welch DF
    Antimicrob Agents Chemother; 1982 Jun; 21(6):939-43. PubMed ID: 6810757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
    Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
    Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine susceptibility tests with ticarcillin and tobramycin in combination should be more appropriate than with each antibiotic alone in cystic fibrosis Pseudomonas aeruginosa.
    Lapointe JR; Bourget C; Mainville S; Lafleur L; Lagacé J; Montplaisir S
    J Chemother; 1989 Jul; 1(4 Suppl):184-6. PubMed ID: 16312360
    [No Abstract]   [Full Text] [Related]  

  • 12. [In vitro bactericidal activity of tobramycin and amikacin alone or in combination against Pseudomonas aeruginosa isolated from patients with cystic fibrosis].
    Bertrou A; Marty N; Henry S; Agueda L; Chabanon G
    Pathol Biol (Paris); 1990 May; 38(5):366-75. PubMed ID: 2114606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
    Ciofu O; Giwercman B; Pedersen SS; Høiby N
    APMIS; 1994 Sep; 102(9):674-80. PubMed ID: 7946270
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
    Prince AS; Neu HC
    Antimicrob Agents Chemother; 1981 Oct; 20(4):545-6. PubMed ID: 6282199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
    Millar BC; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis.
    Foweraker JE; Laughton CR; Brown DF; Bilton D
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4809-15. PubMed ID: 19704123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of
    Mataraci Kara E; Yilmaz M; İstanbullu Tosun A; Özbek Çelik B
    Infect Dis (Lond); 2020 Sep; 52(9):616-624. PubMed ID: 32427010
    [No Abstract]   [Full Text] [Related]  

  • 19. Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa.
    Murphy RA; Coates M; Thrane S; Sabnis A; Harrison J; Schelenz S; Edwards AM; Vorup-Jensen T; Davies JC
    Microbiol Spectr; 2022 Aug; 10(4):e0081322. PubMed ID: 35727066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.
    Yadav R; Bulitta JB; Schneider EK; Shin BS; Velkov T; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.